Immutep Says Root Cause Analysis Identified N-Glycan Structural Differences Between 200 L And 2,000 L Efti Batches Used In Discontinued TACTI-004; Contracts New 200 L Run, Targets Next Trial Start In 2H CY2027
Share
Why It Matters
A company found differences in how they made two batches of medicine, which caused problems in their study. They fixed the process and plan to restart their trial next year.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.